Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events by Jürgen Borlak et al.
Borlak et al. BMC Genomics  (2015) 16:124 
DOI 10.1186/s12864-015-1312-zRESEARCH ARTICLE Open AccessProteome mapping of epidermal growth factor
induced hepatocellular carcinomas identifies
novel cell metabolism targets and mitogen
activated protein kinase signalling events
Jürgen Borlak*, Prashant Singh and Giuseppe GazzanaAbstract
Background: Hepatocellular carcinoma (HCC) is on the rise and the sixth most common cancer worldwide.
To combat HCC effectively research is directed towards its early detection and the development of targeted therapies.
Given the fact that epidermal growth factor (EGF) is an important mitogen for hepatocytes we searched for disease
regulated proteins to improve an understanding of the molecular pathogenesis of EGF induced HCC. Disease regulated
proteins were studied by 2DE MALDI-TOF/TOF and a transcriptomic approach, by immunohistochemistry and advanced
bioinformatics.
Results: Mapping of EGF induced liver cancer in a transgenic mouse model identified n = 96 (p < 0.05) significantly
regulated proteins of which n = 54 were tumour-specific. To unravel molecular circuits linked to aberrant EGFR
signalling diverse computational approaches were employed and this defined n = 7 key nodes using n = 82
disease regulated proteins for network construction. STRING analysis revealed protein-protein interactions of >
70% disease regulated proteins with individual proteins being validated by immunohistochemistry. The disease
regulated network proteins were mapped to distinct pathways and bioinformatics provided novel insight into
molecular circuits associated with significant changes in either glycolysis and gluconeogenesis, argine and proline
metabolism, protein processing in endoplasmic reticulum, Hif- and MAPK signalling, lipoprotein metabolism,
platelet activation and hemostatic control as a result of aberrant EGF signalling. The biological significance of the
findings was corroborated with gene expression data derived from tumour tissues to evntually define a rationale
by which tumours embark on intriguing changes in metabolism that is of utility for an understanding of tumour
growth. Moreover, among the EGF tumour specific proteins n = 11 were likewise uniquely expressed in human
HCC and for n = 49 proteins regulation in human HCC was confirmed using the publically available Human Protein
Atlas depository, therefore demonstrating clinical significance.
Conclusion: Novel insight into the molecular pathogenesis of EGF induced liver cancer was obtained and among
the 37 newly identified proteins several are likely candidates for the development of molecularly targeted
therapies and include the nucleoside diphosphate kinase A, bifunctional ATP-dependent dihydroyacetone kinase
and phosphatidylethanolamine-binding protein1, the latter being an inhibitor of the Raf-1 kinase.
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Liver malignancies are common cancers worldwide and
are responsible for approximately one million deaths
each year with most HCC patients having poor progno-
sis as a result of rapid disease progression. The relative
5-year survival rate is about 15% and can be attributed
to an advanced stage of disease at the time of diagnosis,
the occurrence of cirrhosis and of other co-morbidites
[1]. Detection of early stages of disease is essential for
an improved prognosis and overall survival. However,
apart from alpha-fetoprotein (AFP) only a few sero-
logical markers are available in clinical practice (such
as Glypican-3, miR-21, fucosylated GP73, α-fucosidase)
with AFP diagnostics remaining unsatisfactory because
of its low sensitivity and the non-specific correlation
between the clinical behavior of HCC and AFP blood
levels. For this reason, new biomarkers are in strong
demand [2,3] and more selective markers, such as sol-
uble interleukin-2 receptor levels, are evaluated [4].
Importantly, research into the molecular pathogenesis
of HCC identified several signalling pathways as deregu-
lated. This inspired the development of molecularly tar-
geted therapies such as the multikinase inhibitor sorafenib
that inhibits signalling of C-RAF-1, MEK, ERK, VEGFR,
PDGFR and other kinases, effectively [5]. Given that
epidermal growth factor is an important mitogen for
hepatocytes we were particularly interested in an un-
derstanding of the consequences of its targeted over-
expression in liver. In our initial study we reported the
oncogenomics and pathology of EGF induced hepato-
carcinogenesis and an identification of molecular circuitries
linked to exaggerated EGFR signalling [6]. Furthermore,
we investigated the serum proteome of EGF-tumour-
bearing mice to obtain information on disease-regulated
proteins and to search for novel biomarkers at different
stages of disease [7]. Note, a regulatory loop was proposed
whereby EGF induces transcriptional activation of HDAC2
by CK2Α/AKTactivation in liver cancer cells [8]. Addition-
ally, inhibition of EGFR in different animal models by
Erlotinib was shown to attenuate liver fibrosis and the de-
velopment of hepatocellular carcinoma [9] thus suggesting
new therapeutic intervention strategies in the prevention
of HCC. Indeed, the EGF receptor tyrosin kinase plays a
much wider role in the immortalization of different cell
types as originally anticipated [10], and is highly expressed
in a number of solid tumours and EGFR over-expression
correlates well with tumour progression, resistance to
chemotherapy and poor prognosis.
The present study aimed at an identification of disease
regulated proteins to facilitate an improved understand-
ing of its complex signalling networks and to search for
cross-talk amongst other pathways while an identification of
disease regulated proteins would aid the development of
molecularly targeted therapies.For this purpose, a two-dimensional electrophoresis
(2-DE) and MALDI-TOF/TOF MS strategy was employed
to identify disease regulated proteins in an EGF transgenic
mouse model of HCC. This resulted in an identification of
96 statistically significant regulated proteins of which 54 are
uniquely expressed in liver cancer. Importantly, 11 out of 54
mouse tumour specific proteins were likewise uniquely
expressed in human HCC and 49 disease regulated proteins
identified in EGF induced liver cancer were similarly regu-
lated in human HCC, as determined by immunhistochemis-
try using different antibodies and the information given in
the publically available Human Protein Atlas depository.
Clinical significance of the identified proteins could be dem-
onstrated and a total of 37 so far unkown proteins could
now be related to EGF induced liver cancer, several of which
are likely candidates for the development of molecularly tar-
geted therapies. This includes the nucleoside diphosphate
kinase A, bifunctional ATP-dependent dihydroxyacetone
kinase, phosphatidylethanolamine binding protein1, i.e. an
inhibitor of the RAF-1 kinase as well as aldo-keto reductase
family 1 proteins, members C14 and C6, interleukin 25 and
the v-crk sarcoma virus CT10 oncogene homolog.
Finally, to gain insight into the molecular circuitries of
EGFR induced hepatocarcinogenesis diverse computa-
tional approaches were employed. This revealed master
regulatory proteins and permitted network constructions
of 82 disease regulated proteins with protein-protein inter-
actions being confirmed for > 70% of regulated proteins in
STRING analysis. Their regulations were also studied by
immunohistochemistry in EGF transgenic HCC.
We also compared the serum and liver proteomes of
HCC bearing mice and found 10 proteins to be similarly
regulated, thus evidencing leakage of tumour proteins that
can be detected in serum. Obviously, these are highly inter-
esting biomarker candidates, 6 of which were also regulated
in human HCC as determined by immunohistochemistry.
Methods
Animal studies
All animal work followed strictly the Public Health
Service (PHS) Policy on Humane Care and Use of Labora-
tory Animals of the National Institutes of Health, USA.
Formal approval to carry out animal studies was granted
by the animal welfare ethics committee of the State of
Lower Saxony, Germany (‘Lower Saxony State Office for
Consumer Protection and Food Safety’ (LAVES)). The
approval ID is Az: 33.9-42502-04-06/1204.
A total of n = 12 C57/Bl6 non-transgenic and n = 12 EGF
transgenic mice (aged 6–8 months), weighing 25–33 g,
were housed in Makrolon® Type III cages. Water and food
(V1124-000, SSNIFF, The Netherlands) was given ad
libitum. The temperature and relative humidity was set
to 22 ± 2°C and 40–70%, respectively and a 12-h day
and night cycle was used.
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Tris, urea, thiourea, CHAPS, dithiothreitol, bromophenol
blue, glycerin, sodium dodecyl sulfate, glycine, temed,
ammoniumperoxodisulfate, ammonium sulfate, ammo-
nium bicarbonate, colloidal Coomassie Blue, and acryl-
amide were purchased from Roth (Karlsruhe, Germany).
Iodacetamide was obtained from SERVA (Heidelberg,
Germany) and benzonase was purchased from Novagen
(Darmstadt, Germany). Ampholytes (Biolyte 3–10) were
purchased from Bio-Rad Laboratories (München, Germany)
and DeStreak was obtained from Amersham Bioscience
(Freiburg, Germany).
Mouse liver sample preparation
Mice were anesthetized with ketamine 10% 100 μL/100 g
and xylazine 2% 50 μL/100 g, and after surgical removal
the liver was perfused and rinsed with ice cold Ringer
solution until free of blood.
Approximately 0.1 g of the liver sample was ground in
a mortar under liquid nitrogen flow. Then, the samples
were processed with 0.5 mL of a buffer containing
40 mM tris base, 7 M urea, 4% CHAPS, 100 mM DTT,
and 0.5% (v/v) biolyte 3–10 first (LB2). The suspensions
were homogenized by sonication (3 × 20 s) and after
addition of 3 μL of benzonase (endonuclease that de-
grades DNA and RNA) were left at room temperature
for 20 min. The samples were then centrifuged at
12,000 g for 20 min. The pellets were washed and soni-
cated for 5 min with a further 0.5 mL of LB2 and centri-
fuged at 12,000 g for another 20 min, and the resulting
two fractions of supernatant were collected (extract A).
Finally, the pellets were redissolved with 0.5 mL of buf-
fer containing 40 mM tris base, 5 M urea, 2 M thiourea,
4% CHAPS, 100 mM DTT, and 0.5% (v/v) biolyte 3–10
(LB3), sonicated, and centrifuged at 12,000 g for 20 min.
The pellet was collected, and the supernatant was marked
as extract B.
From the same animals, a further 0.1-g portion was
ground in a mortar, but was now treated with 0.5 mL of
LB3. The suspensions were sonicated, incubated with ben-
zonase, and centrifuged. The pellets were then washed
with another 0.5 mL of LB3, sonicated and centrifuged,
and the supernatants were collected (extract C).
Proteome mapping was done under a variety of condi-
tions, e.g. extraction with lysis buffers 2 and 3. In addition,
proteins were separated at two different pH ranges [5-10].
A total of 4 independent experiments were carried out,
and duplicate measurements were run for each experi-
ment. The protein concentration of all extracts was deter-
mined using the Bradford assay.
Liquid-phase IEF pre-fractionation
Liquid-phase IEF pre-fractionation was performed in the
Rotofor Cell system (Bio-Rad) following the supplier’sinstructions. Ion exchange membranes were equilibrated
overnight in the appropriate electrolyte (anion exchange
membranes in NaOH 0.1 M and cation exchange mem-
branes in H3PO4 0.1 M). After four runs ion exchange
membranes were always discarded and new membranes
were replaced for the other samples. For each run, the
electrode chambers were filled with appropriate fresh elec-
trolytes (30 mL). Initially, the cell was filled with pure
water and run for 5 min at 5 watts constant power to re-
move residual ionic contaminants from the membrane
core and ion exchange membranes. Approximately 32 mL
of LB2 were used to fill the cell. A total of 60 mg of total
proteins in approximately 2 mL of LB2 were added to the
cell to reach the maximum loadable volume (40 mL).
Focusing started at 12 watts constant power. After ap-
proximately 4 hours the voltage increased to 3000 V
and the wattage decreased to 3 W. The focused pro-
teins were harvested in 20 ~ 1.5 mL fractions, and pH
values were checked. Fractions having pH values between
3 and 7.0 were collected and denoted “A-a” (acid). Frac-
tions having pH values > 7.0 were collected and denoted
“A-b” (basic). Again, the protein concentration was deter-
mined for both fractions (A-a and A-b) by the Bradford
method. Approximately 30 mg of protein were recovered
at the end of the liquid-phase IEF pre-fractionation from
an initial 60-mg load. The losses are accounted for by the
multi-step pre-fractionation procedure, but are not the re-
sult of a precipitate that could not be dissolved in our lysis
buffer. After each run the membrane core was cleaned
with NaOH 0.1 M overnight and sonicated for 5 min in
water before the new focusing.
Two-dimensional gel electrophoresis
Isoelectric focusing (IEF) - first dimension
IEF was performed using precast linear IPG strips. The
17-cm IPG strips 7–10 and 5–8 were loaded with 1.5 mg
of proteins by active rehydration (12 h, 50 V). Samples
destined to be separated by IPG strips 7–10 received an
excess of hydroxyethyldisulphide (HED) (DeStreak™) prior
to the focusing run. Focusing began at 250 V for 20 min in
rapid mode, 10,000 V for 5 h in linear mode and 10,000 V
for 50,000 Vh in rapid mode (for the IPG strips 5–8). IEF
for the strips 7–10 was carried out at 250 V for 60 min in
rapid mode, 10,000 V for 3 h in linear mode and 10,000 V
for 50,000 Vh in rapid mode. Each sample was analysed in
duplicate. Control and HCC samples were run always at
the same time (6 control and 6 HCC samples).
2-DE - second dimension
After IEF, the IPG strips were either stored at −80°C or
transferred to 10 mL of equilibration buffer (6 M urea,
30% w/v glycerin, 2% w/v SDS, 50 mM Tris–HCl pH 8.8)
with 2% w/v DTT and 0.5% v/v bromophenol blue solu-
tion (0.25% w/v bromophenol blue, 1.5 M Tris–HCl
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temperature. Strips were removed and incubated in equili-
bration buffer with 4% w/v iodoacetamide and 0.5% v/v
bromophenol blue solution for further 20 min at room
temperature. Finally, the strips and 10 μL SDS-PAGE mo-
lecular weight standard on filter paper were placed on top
of the 20 cm x 20.5 cm 12% second-dimension gel (12% v/
v acrylamide/bis solution, 375 mM Tris, pH 8.8, 0.1% v/v
SDS, 1/2000 TEMED, 0.05% v/v APS). Both were fixed in
place with a 0.5% w/v agarose overlay. Gels were run in
PROTEAN Plus Dodeca cell (Bio-Rad) at 70 V for ap-
proximately 14 h, followed by 200 V until the bromophe-
nol blue dye reached the bottom of the gel. The running
buffer (25 mM Tris, 0.2 M glycin, 0.1% SDS) was cooled
externally to 16°C.
Gels/proteins were fixed overnight in 30% ethanol, 2%
phosphoric acid, and washed 3 x 20 min with 2% phos-
phoric acid. The gels were equilibrated with 15% ammo-
niumsulfate, 18% ethanol, 2% phosphoric acid for 15 min
and finally stained with colloidal Coomassie Blue for 48 h.Gel scanning and image analysis
After staining, gels were washed 10 min with pure water and
scanned on a Molecular FX Scanner (Bio-Rad) at 100 μm
resolution. Protein spots were imaged first automatically and
then manually and analysed using the PDQuest™ soft-
ware (Bio-Rad). The normalization was carried out in
total density in gel mode according to the manufac-
turer’s recommendation.Matrix-assisted laser desorption ionization mass
spectrometry (MALDI-MS)
Gels were excised using the spot cutter of Bio-Rad and
placed into 96-well microtiter plates. Excised gel spots
were washed manually with 20 μL of water for 10 min and
destained twice, first with 15 μL ammonium bicarbonate
50 mM for 5 min and then with 15 μL 50% ammonium bi-
carbonate 50 mM – 50% acetonitrile for 5 min. Finally,
the gel particles were covered by acetonitrile until gel
pieces shrunk and left to dry for 10 min. All gels/proteins
were digested manually in situ with 4 μL of ammonium
bicarbonate 50 mM containing 20 ng trypsin (Sequencing
Grade Modified Trypsin, Promega, Germany). After
15 min each gel piece was re-swelled with 10 μL of am-
monium bicarbonate 50 mM and incubated for 4 h at
37°C. After 4 h the reaction was stopped by adding
10 μL of trifluoroacetic acid 1% containing 1.5% (w/v)
n-octyl-beta-D-glucopyranoside (OGP) (AppliChem). For
the application of the samples, 4 μL of peptide solution
were loaded onto an MTP Anchor Chip Target 600/384
(Bruker Daltonics) previously prepared with a saturated
solution of matrix, alpha-cyano-4-hydroxy-cinnamic acid
(alpha-HCCA) (Bruker Daltonics, Bremen, Germany).MALDI-MS was performed on an Ultraflex II MALDI-
TOF/TOF (Bruker Daltonics) mass spectrometer equipped
with a SmartBeam™ laser and a LIFT-MS/MS facility. The
instrument was operated in positive ion reflectron mode
and an acceleration voltage of 25 keV for the Peptide Mass
Fingerprint (PMF) mode. Typically, 600 spectra, acquired
at 100 Hz, were summed and externally calibrated. In the
case of MS/MS-CID the LIFT device was used for selection
and fragmentation of the ions; the acceleration voltage in
the ion source 8 kV, the Timed Ion Selector was set to 0.4%
(relative to parent mass), and argon was used as collision
gas (~4-6 × 10–6 mbar). Resulting fragments were further
accelerated in a second source by 19 kV and analysed by a
two-stage gridless reflectron. Typically, 400 shots were ac-
cumulated for the parent ion signal and 1000 shots for the
fragments. FlexControl™ 3.0, and FlexAnalysis™ 3.0 were
used as instrument control and processing software (Bruker
Daltonics, Bremen, Germany).
A calibration standard was used for the external calibra-
tion of spectra (Peptide Calibration Standard for Mass Spec-
trometry, which covered the mass range ~1000-4000 Da
(Bruker Daltonics). Typically, 1 μL of the peptide calibration
standard was spotted on 96 calibration positions of the
Anchor Chip Target (Bruker Daltonics) containing the fol-
lowing peptides: angiotensin II (1046.5420 Da), angiotensin I
(1296.6853 Da), substance P (1347.7361 Da), bombesin
(1619.8230 Da), ACTH clip 1–17 (2093.0868 Da), ACTH
clip 18–39 (2465.1990 Da), somatostatin 28 (3147.4714 Da)
and OGP 1.5% (w/v).
Internal calibration was achieved using trypsin autoly-
sis products (m/z’s 1045.564, 2211.108 and 2225.119)
resulting in a mass accuracy of ≤ 50 ppm. Spectra were
collected by the FlexControl software without smoothing
or baseline subtraction and a peak resolution higher than
6000 or 7000 a.u. in case of DHB and CHCA matrix-
sample preparation, respectively. The spectra were sent to
the FlexAnalysis software which labeled the peaks for
protein identification by ProteinScape 1.3 or BioTools
3.1 (Bruker Daltonics).
Trypsin autolysis products, tryptic peptides of human
keratin and matrix ions were automatically discarded by
ProteinScape (mass control list). ProteinScape Score Booster
feature was used to improve database search results by auto-
matic iterative recalibrations and background eliminations.
Protein scores greater than 53 were considered significant
(p <0.05, Mascot) and an annotation as mouse protein as
the top candidates was requested in the search when no re-
striction was applied to the species of origin. Identified pro-
teins were checked individually for further considerations.
For PMF peak picking the snap peak detection algo-
rithm, a signal to noise threshold of 6, maximal number
of peaks 100, a quality factor threshold 50 and baseline sub-
traction TopHat was applied. Peptide masses were searched
against the Swiss-Prot database (download 2005–197 228
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server (in-house MASCOT-server, Matrix Sciences Ltd.,
http://www.matrixscience.com/, revision 2.0.0), taking into
account carbamidomethyl of cysteines -Carbamidomethyl
(C)- as fixed modification and possible oxidation of me-
thionine -Oxidation (M)- as a variable modification but
allowing one missed cleavage. Based on initial data, ion
precursors were selected by ProteinScape for tandem MS
data acquisition (by LIFT-TOF/TOF, Bruker Daltonics,
Bremen, Germany). In the MASCOT MS/MS ions search,
the restriction Mammalia was applied with peptide toler-
ance of (70 ppm and MS/MS tolerance of (0.9 Da (fixed
and variable modifications as PMF). The acceptance cri-
teria for PMF-based identification were an individual ions
score >27, at least five matching peptides and 10% peptide
coverage of the theoretical sequences.
Immunohistochemistry
Livers, dissected from EGF-overexpressing mice aged
between 7–9 months, were fixed in 4% buffered parafor-
maldehyd and embedded in paraffin. 5 μm thick sections
were deparaffinized and rehydrated through a descend-
ing alcohol series followed by a 4 min washing step in
destilled H2O. Subsequently, antigen retrieval was per-
formed in citrate buffer (pH 6) by autoclaving the sections
15 min at 121°C. The Envision kit (Dako, Hamburg,
Germany) was used for immunohistochemistry.
The slides were rinsed with destilled H2O and after a
5 min incubation step in tris-buffered saline (washing
buffer), endogenous peroxidase activity was blocked with
DAKO Peroxidase blocking Reagent for 5 min followed
by a second washing step. Thereafter, the sections were
blocked for 10 min with protein-block serum free (Dako)
and incubated with primary antibodies for 45 min. Details
of antibody dilutions with washing buffer are given in
Additional file 1: Table S1. In the case of goat primary
antibodies a rabbit-anti-goat bridging antibody (Dako) was
employed. Specifically, the bound primary antibodies or
bridging antibodies were detected by use of labelled poly-
mer HRP Anti-Rabbit secondary antibody (Envision Kit;
Dako) and the immunoreactivity was visualized by DAKO
Liquid DAB Substrate Chromogen System in a 5 min
incubation.
Finally, the sections were counterstained with Harris
Haematoxylin for 2 min, dehydrated in an ascending alco-
hol series, coverslipped and examined under a light micro-
scope (Leica, Jülich, Germany).
Bioinformatic analysis
A total of n = 122 disease regulated proteins were filtered
for statistical significance at p < 0.05 (Table 1). This yielded
n = 96 statistically significantly regulated proteins two of
which had identical accession number, i.e. AAH81431 =
ATP synthase H+ transporting mitochondrial F0 complex,subunit d and BAC36241 =APOA1 but differed in their
spot IDs as a result of posttranslational modifications. The
statistically significantly regulated proteins were grouped
into four different categories to yield 54 tumour specific
(To), 9 up-regulated (UR), 19 down-regulated (DR) and 14
proteins only expressed in healthy non-transgenic control
livers (Co).
Categorization of tumour regulated proteins based on
ontology terms
82 non-redundant tumour proteins covering To, UR and
DR categories were considered and analysed for Ontologies
using the GeneXplain software (v.2.4.1), the biological path-
ways tools Reactome (http://www.REACTOME.org)
and KEGG (http://www.genome.jp/kegg) and WikiPath-
ways (http://wikipathways.org). The tumour regulated
proteins (To +UR +DR) were subjected to functional clas-
sification based on ontology terms and a p-value of <0.01
was considered to be significant. Moreover, disease regu-
lated proteins were analysed with the Cytoscape software
version 3.0.2 using the function GO-tree levels and num-
ber or % of proteins for a given term (see Additional file 2:
Table S2).
Identification of master regulatory molecules and protein
network construction for tumour proteins
Master regulatory proteins were searched based on the
designated workflow of the GeneXplain software. It is de-
signed to find master regulatory molecules upstream of an
input list of regulated tumour proteins. After annotation
of the input datasets the tool for master regulator finding
over GeneWays network (http://www.genexplain.com)
was applied. Specifically, the GeneWays software is used
to automatically extract, analyse, visualise and integrate
molecular pathway data from the published peer reviewed
literature. It is based on document sorting, term identifica-
tion, term meaning disambiguation, information extrac-
tion, ontology, visualization and system integration [61].
The following filtering threshold was used, i.e. score cut-
off (0.2), search collection (GeneWays hub), maximum
radius [4,10], FDR cutoff (0.05), Z-score cutoff (1.0), Pen-
alty (0.1) and Decay factor (0.1) (Additional file 3: Table
S3).
Protein network for disease regulated proteins were
also constructed using the STRING software (http://
string-db.org/). The underlying database informs on
known and predicted protein-protein interaction and
the constructed networks are based on active prediction
methods of Neighborhood, Gene Fusion, Co-occurrence,
Co-expression, Databases and Textmining. Eventually, con-
fidence scores were calculated for each interaction pair and
only those above default cutoff scores (0.4) were selected.
Finally, mapping of pathways information from REAC-
TOME, KEGG and WikiPathways have been implemented
Table 1 Disease regulated proteins in HCC of EGF transgenic mice





Gene Symbol Mr pI Mascot score Gels C T LB2 LB3 p-value Ratio T/C Cellular
location
References
1 170 kDa glucose regulated protein
GRP170 precursor
7643979 AAF65544 Hyou1 111 5 214 10 0 10 8 2 T ER, ES [11,12]
2* 2-hydroxyphytanoyl-CoA lyase 18204150 AAH21360 Hacl1 64 5.9 261 32 19 13 22 10 0.027 0.38 P
3 3-phosphoglycerate dehydrogenase 52353955 NP_058662 Phgdh 57 6 204 14 0 14 11 3 T [13]
4* 4931406C07Rik (Ester hydrolase C11orf54
homolog) (spot 4342)
71059921 CAJ18504 4931406C07Rik 35 5.8 184 35 17 18 24 11 0.033 1.5 N
5* 4931406C07Rik (Ester hydrolase C11orf54
homolog) (spot 4349)
71059921 CAJ18504 4931406C07Rik 35 5.8 195 33 15 18 22 11 0.244 1.9 N
6 Acylpeptide hydrolase; N-acylaminoacyl
peptide hydrolase
22122789 NP_666338 Apeh 80 5.2 182 5 0 5 0 5 T [14]
7* Aldo-keto reductase family 1, member C12 15215042 AAH12643 Akr1c12 37 6.1 135 24 14 10 15 9 0.301 1.9
8 Akr1c18 protein (aldo-keto reductase
family 1, member C18)
19527284 NP_598827 Akr1c18 37 5.9 189 11 0 11 5 6 T C [15]
9* Alanyl-tRNA synthetase 34610207 NP_666329 Aars 107 5.4 178 4 0 4 0 4 T C
10 Albumin 1 (spot 3707) 33859506 NP_033784 Alb 69 5.7 444 43 21 22 31 12 0.068 3.88 C, ES [15,16]
11 Albumin 1 (spot 3712) 33859506 NP_033784 Alb 69 5.7 416 40 20 20 30 10 0.25 2.04 C, ES [15,16]
12 Albumin 1 (spot 4506) 33859506 NP_033784 Alb 69 5.7 423 40 20 20 31 9 T C, ES [15,16]
13 Albumin 1 (spot 4702) 33859506 NP_033784 Alb 69 5.7 355 42 20 22 31 11 0.069 1.85 C, ES [15,16]
14 Albumin 1 (spot 5509) 33859506 NP_033784 Alb 69 5.7 473 38 18 20 30 8 0.392 3.59 C, ES [15,16]
15* Aldo-keto reductase family 1, member C14 19527294 NP_598833 Akr1c14 37 5.9 189 11 0 11 5 6 T
16* Aldo-keto reductase family 1, member C6 13487925 NP_085114 Akr1c6 37 8.5 120 10 0 10 7 3 T C
17 Aldolase 1, A isoform 53733633 AAH83932 Aldoa 39 9.2 213 12 1 11 11 1 T [17]
18* Aldolase 3 60687506 NP_033787 Aldoc 39 6.5 153 5 0 5 4 1 T M
19 Alpha enolase (spot 4501) 58476212 AAH89539 Gm5506 or
Enol1
47 6.4 341 45 22 23 33 12 0.24 0.22 C [3,13,18,19]
20 Alpha enolase (spot 4516) 58476212 AAH89539 Gm5506 or
Enol1
47 6.4 338 40 21 19 30 10 0.161 0.47 C [3,13,18,19]
21 Alpha enolase (spot 4524) 58476212 AAH89539 Gm5506 or
Enol1
47 6.4 338 42 22 20 31 11 0.021 0.53 C [3,13,18,19]
22 Alpha enolase (spot 5510) 58476212 AAH89539 Gm5506 or
Enol1
47 6.4 330 45 22 23 34 11 0.234 0.76 C [3,13,18,19]
23* Alpha glucosidase 2 26326711 BAC27099 Ganab 107 5.6 269 5 0 5 0 5 T ER, G
24 Annexin A6 31981302 NP_038500 Anxa6 76 5.3 267 5 0 5 0 5 T C [14,16]
25 Apolipoprotein A-IV 14789706 AAH10769 Apoa4 45 5.3 224 21 6 15 18 3 0.011 2.77 ES [20]
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27 Apolipoprotein A-I (spot 2215) 26345182 BAC36241 Apoa1 31 5.4 173 38 21 17 28 10 0.001 5.4 S [13,20,22]
28 Apolipoprotein A-I (spot 3204) 26345182 BAC36241 Apoa1 31 5.4 170 30 18 12 T S [20,22]
29 Arginase 1, liver 7106255 NP_031508 Arg1 35 6.6 306 38 23 15 28 10 0.013 0.32 C [3,13,23,24]
30* Arginase type II 6753110 NP_033835 Arg2 39 6.1 161 6 0 6 6 0 T M
31 Argininosuccinate synthetase 1 6996911 NP_031520 Ass1 47 8.5 175 15 15 0 10 5 C M [25-31]
32 ATP synthase, H+ transporting,
mitochondrial F0 complex, subunit d
(spot 2120)
51980458 AAH81431 Atp5h 19 5.3 148 37 20 17 25 12 0.002 0.33 M [32]
33 ATP synthase, H+ transporting,
mitochondrial F0 complex, subunit d
(spot 3203)
51980458 AAH81431 Atp5h 19 5.3 145 35 19 16 22 13 C M [32]
34* Beta 5-tubulin 18088719 AAH20946 Tubb 50 4.7 267 11 1 10 7 4 T Ck
35* Branched chain ketoacid dehydrogenase
E1, alpha polypeptide
31982494 NP_031559 Bckdha 50 8.4 237 26 18 8 20 6 0.018 0.5 MM
36* Butyryl Coenzyme A synthetase 1 16905127 NP_473435 Acsm1 65 6.6 119 4 4 0 0 4 C MM
37 Cai protein (Pdia4) 45219865 AAH66857 Pdia4 65 5.9 267 5 0 5 1 4 T ER
38 Capping protein alpha 1 subunit (Capza1) 595917 AAC00566 Capza1 33 5.2 114 11 0 11 7 4 T Ck [13]
39 Carbamoyl-phosphate synthetase 1,
mitochondrial
8393186 NP_058768 Cps1 165 6.3 350 31 22 9 22 9 0.023 0.2 M, C [14,15,31,33,34]
40 Carboxylesterase MH1 14331135 BAB60698 Ces1d 62 6.2 168 4 0 4 0 4 T ER [17,35]
41* cDNA sequence BC021917
(dihydroxyacetone kinase 2 homolog)
21703976 NP_663471 Dak 60 6.3 170 4 0 4 1 3 T
42 Creatine kinase 10946574 NP_067248 Ckb 43 5.3 181 4 0 4 0 4 T M, C [13]
43 Cryz protein 13277837 AAH03800 Cryz 35 8.2 84 5 5 0 5 0 C C [36]
44 Cu/Zn superoxide dismutase 1513495A 226471 1513495A Sod1 16 5.9 186 39 21 18 27 12 0.007 2.92 [13,22]
45 DEMSMC malate dehydrogenase,
cytosolic
319837 P14152 Mdh1 37 5.9 138 31 17 14 19 12 4E-05 0.27 C [37]
46* Dhdh (dihydrodiol dehydrogenase
(dimeric)) protein
21618806 AAH31710 Dhdh 37 5.7 209 26 17 9 16 10 1E-04 0.17
47* Diacetyl/L-xylulose reductase 50400594 Q91X52 Dcxr 26 7.8 228 5 5 0 0 5 C MEM
48* Dmgdh protein (Dimethylglycine
dehydrogenase, mitochondrial)
12836171 BAB23536 Dmgdh 97 7.6 184 8 8 0 5 3 C M
49* Enoyl coenzyme A hydratase 1,
peroxisomal
7949037 NP_058052 Ech1 36 7.4 162 26 11 15 21 5 0.026 0.49 M, P
50 Eukaryotic translation elongation factor 2 33859482 NP_031933 Eef2 95 6.3 208 6 0 6 3 3 T C [38]
51 Eukaryotic translation initiation factor 5A
(eIF-5A)
124231 NP_001160068 Eif5a 17 5.1 115 10 5 5 7 3 0.106 3.4 C, N [14]













Table 1 Disease regulated proteins in HCC of EGF transgenic mice (Continued)
53* Fatty acid binding protein 5, epidermal 6754450 NP_034764 Fabp5 15 6.2 149 15 2 13 13 2 0.09 27.9 C
54 Fibrinogen, alpha polypeptide 33563252 NP_034326 Fga 61 7 144 15 0 15 10 5 T [31,34]
55 Fibrinogen, B beta polypeptide (spot 5602) 33859809 NP_862897 Fgb 55 6.5 238 35 15 20 23 12 0.001 2.41 ES [34]
56 Fibrinogen, B beta polypeptide (spot 5612) 33859809 NP_862897 Fgb 55 6.5 244 33 15 18 22 11 0.187 3.54 ES [34]
57 Fibrinogen, gamma polypeptide 18044708 AAH19828 Fgg 49 5.5 196 12 1 11 5 7 T ES [31,40]
58 FK506 binding protein 4 6753882 NP_034349 Fkbp4 52 5.5 154 4 0 4 1 3 T C, N [13,14]
59 GDP dissociation inhibitor 2 (GDI 2) 38197560 AAH61767 Gdi2 51 5.8 220 5 0 5 0 5 T G, C,
MEM
[14]
60 Glutathione peroxidase 1 6680075 NP_032186 Gpx1 22 6.2 215 25 18 7 18 7 2E-05 0.28 C, M [41-43]
61 Glutathione S-transferase, mu 2 6680121 NP_032209 Gstm2 26 7.6 222 11 1 10 7 4 T C [14,15]
62 Glycine N-methyltransferase (spot 4256) 34013296 AAL06142 Gnmt 33 6.9 214 23 23 0 17 6 C C [15,40,44,45]
63 Glycine N-methyltransferase (spot 5269) 34013296 AAL06142 Gnmt 33 6.9 226 22 22 0 15 7 C C [15,40,44,45]
64 Glycine N-methyltransferase (spot 9105) 34013296 AAL06142 Gnmt 33 6.9 218 20 20 0 15 5 C C [15,40,44,45]
65 Glycyl-tRNA synthetase 21264024 Q9CZD3 Gars 82 6.2 180 5 0 5 0 5 T C [46]
66 Haao protein (3-hydroxyanthranilate
3,4-dioxygenase)
15277547 AAH12872 Haao 33 6 420 35 22 13 27 8 0.006 0.24 C [14]
67 Hal (histidine ammonia lyase) protein 35505393 AAH57637 Hal 72 5.9 301 6 6 0 0 6 C C [47]
68 Hemopexin 23956086 NP_059067 Hpx 51 9 231 16 2 14 11 5 0.323 7.27 ES [48]
69 Heterogeneous nuclear
ribonucleoprotein L (hnRNPL)
33667042 NP_796275 Hnrnpl 60 6.6 156 8 0 8 8 0 T N [13]
70 HSP60 (spot 2604) 1334284 CAA37654 Hspd1 58 5.3 298 15 7 8 6 9 0.008 0.4 MM [13,14,35]
71 HSP60 (spot 2610) 1334284 CAA37654 Hspd1 58 5.3 298 14 7 7 6 8 0.012 0.5 MM [13,14,35]
72* Hypothetical protein LOC68347 58037115 NP_080962 0610011F06Rik 23 5.8 125 29 15 14 21 8 0.014 0.39
73* Inosine triphosphatase 31982664 NP_080198 Itpa 22 5.4 139 5 0 5 5 0 T C
74 Interleukin 1 receptor antagonist protein 238585 AAB20265 Il1rn 18 5.5 121 7 0 7 6 1 T S, C [35-37,41-43,45-50]
75* Interleukin 25 or UPF0556 protein
C19orf10 homolog precursor
18250288 NP_543027 D17Wsu104e 18 5.9 89 13 6 7 9 4 0.23 2.1 ES
76* Kininogen 1 12963497 NP_075614 Kng1 48 5.7 217 21 8 13 19 2 0.091 2.8 ES
77 Lamin-A/C 15929761 AAH15302 Lmna 74 6.6 199 12 0 12 10 2 T N [13,15]
78* LIM and SH3 protein 1 6754508 NP_034818 Lasp1 30 6.7 156 7 0 7 6 1 T Ck
79 Liver fructose-1,6-bisphosphatase 6688689 CAB65244 Fbp1 37 6.2 281 29 18 11 17 12 0.013 0.35 [14,34,40]
80* Lysophospholipase 1 6678760 NP_032892 Lypla1 25 5.9 134 25 13 12 20 5 0.25 0.25 M
81 Major urinary protein 1839508 AAB47130 Mup14 19 4.7 138 6 6 0 6 0 C S [51,52]
82* Major vault protein 12003287 AAG43520 Mvp 96 5.4 238 4 0 4 0 4 T C













Table 1 Disease regulated proteins in HCC of EGF transgenic mice (Continued)
MAWD binding protein homolog 1 or
Phenazine biosynthesis-like domain-
containing protein 1
84* Mitochondrial acyl-CoA thioesterase 1 OR
Acyl-CoA thioesterase 2
40538846 NP_598949 Acot2 50 7 123 6 6 0 1 5 C M
85 NADH dehydrogenase (ubiquinone) 1
alpha subcomplex, 8
21312012 NP_080979 Ndufa8 20 8.8 145 4 4 0 4 0 C M [34,53]
86 NADH dehydrogenase (ubiquinone)
Fe-S protein 1 (Ndufs1)
26331822 BAC29641 Ndufs1 80 5.5 240 5 5 0 0 5 C M [14]
87 NADH dehydrogenase (ubiquinone)
flavoprotein 1
19526814 NP_598427 Ndufv1 51 8.5 151 4 0 4 3 1 T M, ES [53]
88 Nit protein 2 (spot 5315) 12963555 NP_075664 Nit2 31 6.2 347 34 18 16 24 10 C [3,13]
89 Nit protein 2 (spot 6201) 12963555 NP_075664 Nit2 31 6.2 345 30 16 14 22 8 0.295 0.8 [3,13]
90* Nucb1 (nucleobindin 1) protein 49117484 AAH72554 Nucb1 53 5 184 8 0 8 8 0 T G, C,
MEM
91 Peroxiredoxin 6 (spot 4207) 6671549 NP_031479 Prdx6 25 5.7 282 40 21 19 30 10 0.132 2.3 C, L [3]
92 Peroxiredoxin 6 (spot 5216) 6671549 NP_031479 Prdx6 25 5.7 280 38 20 18 28 10 0.018 0.3 C, L [3]
93 Phosphatidylethanolamine binding
protein
53236978 AAH83063 Pebp1 21 5.2 135 12 2 10 11 1 0.008 2.2 C [22,40,53]
94 Plasminogen 200403 AAA50168 Plg 91 6 243 9 0 9 6 3 T S [33,54-56]
95* Poly(rC) binding protein 2;
heterogeneous nuclear ribonucleoprotein
X or Poly(rC) binding protein 1
6754994 NP_035995 Pcbp1 38 6.4 189 8 0 8 8 0 T N
96 Agmatine ureohydrolase (agmatinase) 20848362 XP_131722 Agmat 38 8 108 24 16 8 19 5 0.003 0.1 ES
97 Prohibitin 54035592 AAH83354 Phb 30 5.4 335 39 21 18 28 11 0.018 0.6 M [13]
98* Psmd11 (proteasome (prosome,
macropain) 26S subunit, non-ATPase, 11)
protein
33585718 AAH55457 Psmd11 47 6.1 258 4 0 4 0 4 T C
99 Pyridoxine 5′-phosphate oxidase 19527238 NP_598782 Pnpo 30 8.4 120 24 14 10 16 8 0.026 0.3 [15,40]
100 Pyruvate kinase 3 or pyruvate kinase,
muscle isoform M2
31981562 NP_035229 Pkm 58 7.9 274 7 0 7 4 3 T M [57]
101 Pzp protein (a2-macroglobulin) or
Pregnancy zone protein
34785996 AAH57983 Pzp 166 6.2 151 14 2 12 9 5 T ES [58]
102 Retinol binding protein 4, plasma 33859612 NP_035385 Rbp4 23 5.6 144 19 2 17 14 5 0.129 12.7 ES [3]
103* RIKEN cDNA 1810013B01 (abhydrolase
domain containing 14b)
27753960 NP_083907 Abhd14b 23 5.6 172 31 16 15 23 8 0.042 0.6 N, C
104* RIKEN cDNA 2410004H02 or Aldehyde
dehydrogenase family 16 member A1
26080429 NP_666066 Aldh16a1 85 5.8 114 4 0 4 0 4 T













Table 1 Disease regulated proteins in HCC of EGF transgenic mice (Continued)
106* Sars1 protein or Seryl-aminoacyl-tRNA
synthetase
14250361 AAH08612 Sars 58 5.9 199 4 0 4 0 4 T C
107 Selenium binding protein 1 22164798 NP_033176 Selenbp1 53 5.9 336 31 19 12 21 10 0.061 0.5 C, MEM,
N
[14]
108 Serine (or cysteine) proteinase inhibitor,
clade B, member 6a
6678097 NP_033280 Serpinb6a 43 5.4 137 5 0 5 0 5 T C [13]
109* Serpinb1a protein 12834891 BAB23079 Serpinb1a 43 5.7 255 8 8 0 4 4 C C
110 Serum amyloid P-component 38174334 AAH61125 Apcs 26 6 141 4 0 4 0 4 T ES [14-16]
111* Sorcin 13385076 NP_079894 Sri 20 4.9 129 7 0 7 6 1 T C, MEM
112* T43799 proteasome protein p45/SUG
[imported]
11265288 P62198 Psmc5 46 7.6 222 6 0 6 6 0 T C, N
113 T-complex protein 1, theta subunit
(TCP-1-theta) (CCT-theta)
12846632 BAB27244 Cct8 50 5.5 189 5 0 5 0 5 T C [15]
114 Transglutaminase 2, C polypeptide 6678329 NP_033399 Tgm2 77 5 240 6 0 6 3 3 T C, MEM [14]
115 Transthyretin 7305599 NP_038725 Ttr 16 5.5 127 18 6 12 12 6 0.169 3 ES [16,20]
116 Tumor metastatic process-associated pro-
tein NM23
51980604 AAH82178 Nme1 17 6.4 134 9 0 9 7 2 T [13,14]
117* Uap1l1 (UDP-N-acteylglucosamine
pyrophosphorylase 1-like 1) protein
28175154 AAH43307 Uap1l1 57 5.2 168 4 0 4 0 4 T
118 UDP-glucose dehydrogenase 6678499 NP_033492 Ugdh 55 7.4 307 14 0 14 13 1 T [46]
119 Galectin-3 or Lectin, galactose binding,
soluble 3
52987 CAA34736 Lgals3 28 8.8 136 6 0 6 5 1 T N, C [13]
120* v-crk sarcoma virus CT10 oncogene
homolog
56205173 CAI24083 Crk 34 5.3 187 8 0 8 8 0 T C, MEM
121 Vimentin 31982755 NP_035831 Vim 54 5 260 26 11 15 21 5 0.022 4 Ck [13,35]
122 Vitamin D-binding protein 193446 AAA37669 Gc 53 5.2 229 32 15 17 22 10 0.175 1.6 ES [59,60]
Abbreviations: C, cytosol; Ck, cytoskeleton; M, mitochondria; N, nucleus; P, peroxisome; ES, extracellular space; ER, endoplasmic reticulum; G, golgi; L, lysosome; MEM, membrane; MM, mitochondrial matrix; S, secreted.
The proteins are sorted in alphabetical order, and the NCBI annotation is given in the accession number column. Molecular weight, pI, and MASCOT scores are also given. The column “Gels”, “C” (C = control) and “T”
(T = tumour) indicate the frequency of positive identification of proteins in a total of 48 independent gels, whereas “LB2” and “LB3” (LB = lysis buffer) refers to the different lysis buffers employed. Furthermore,
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ways and sustained proteins connecting these pathways in
a given network.
Results
The histopathology and oncogenomics of EGF induced
liver cancers was previously reported [6] and an import-
ant finding of the study was the 100% incidence of ma-
lignant tumour formation in less than one year after
birth. Notably, a sequence of events was observed that
initially consisted of diffuse large cell dysplasia followed
by multiple dysplastic foci and nodules and growth of
HCC. Figure 1 A and B depict the histopathology of
healthy non-transgenic control liver and EGF induced
tumours, respectively.
Image analysis of differentially expressed proteins
After protein extraction 2DE was performed. Subse-
quently, the gels were scanned on a Bio-Rad Molecular
FX Scanner at a 100 μm resolution. Image analysis was
done with the PDQuestTM software and spots were de-
tected automatically. A total of 122 proteins differed in
expression or were de novo expressed when 2DE gels of
non-transgenic controls and HCC mice were compared
(see Table 1 for detailed information on the proteins
identified and Figure 1E-G depicting examples of zoom-
in-gels of some regulated proteins). Among them are 96
statistically significantly regulated proteins (p ≤ 0.05) of
which 63 were significantly up-regulated (ratioHCC/con-
trol ≥ 2) and included fibrinogen and subunits of it,
vimentin, Cu/Zn superoxide dismutase, and apolipopro-
tein E (Figure 1F (I-IV), while 33 proteins were re-
pressed in expression (ratioHCC/control ≤ 0.6) and included
arginase 1, Dhdh protein, glutathione peroxidase 1 and
agmatine ureohydrolase (Figure 1G (I-IV) and Table 1).
Identification of proteins by MS analysis
A reference 2-DE map of mouse liver and serum pro-
teins was constructed that consists of more than n = 500
proteins [2,7]. Note, in our previous efforts we identified
n = 25 serum proteins as regulated in the EGF transgenic
disease model. Among them were alpha-fetoprotein,
clusterin, fibrinogen-α and -γ, serum amyloid compo-
nent P and several apolipoproteins all of which were sig-
nificantly up-regulated. Based on the combined use of
2DE and MALDI-MS a total of n = 122 differentially
expressed proteins were identified (Table 1) and in-
cluded isoforms as well as post translational modifica-
tions of albumin (5 up-regulated spots), alpha enolase (4
down-regulated spots), apoliproptein A-I (2 up-regulated
spots), ATP synthase H+ transporting mitochondrial (2
down-regulated spots), fibrinogen beta (2 up-regulated
spots), glycine N-methyltransferase (3 spots, in controls
only), hsp60 (2 down-regulated spots), nit protein 2 (2down-regulated spots), peroxiredoxin 6 (1 up-regulated
spot and 1 down-regulated spot), and 4931406C07Rik (2
up-regulated spots) (see Table 1). Importantly, a total of
n = 37 so far unknown disease regulated proteins were
identified that can now be related to EGF induced liver
cancer. These are marked with an asterisk in Table 1.
Furthermore, a comparison of serum and liver pro-
teoms revealed n = 10 proteins to be regulated in com-
mon, thus evidencing leakage of tumour proteins into
systemic circulation (Table 2). Among them was serum
AFP; it’s up-regulation and that of others was confirmed
by Western blot analysis (Figure 2A-E). Likewise, apoli-
poprotein E was up-regulated both in serum and tumour
samples, the ratio HCC/control being 2.2 and 3.9, re-
spectively. In a previous study on human HCC increased
expression of ApoE was observed in 88% of study cases;
however, gene ApoE expression and serum levels were
unchanged to suggest its accumulation and impaired se-
cretion [21]. Two isoforms of alpha-2-macroglobulin
were up-regulated in serum of HCC-bearing mice (spot
1: ratioHCC/control = 1.8; spot 2: ratioHCC/control = 3.2). Its
expression was exclusively associated with tumours. Fi-
nally, serum amyloid component P was up to 10-fold
up-regulated in serum and its tissue expression was
tumour specific (Table 2).
Immunohistochemistry of disease-regulated proteins
To further evidence disease regulated proteins and to
provide information on their subcellular localization a
total of n = 8 proteins were studied by immunohisto-
chemistry. Five of them were selected for their novelty
(see Table 1) while amphiregulin and epiregulin were
chosen for their importance in the EGF-signalling path-
way. Furthermore, HNF4α was studied for its pivotal
role in liver cancer [62]. Depicted in Figure 3 are immu-
nohistochemistry stainings performed with EGF trans-
genic livers to confirm regulation and predominant
cytoplasmic expression of arginase II. Note, ARG2 is
only expressed in HCC and recent evidence suggest
modulation of arginine levels in the extracellular milieu
to be part of an immune escape mechanism whereby
lack of local arginine weakens tumour-infiltrating lym-
phocytes as T cells require adequate argine levels [63].
Likewise, the tumour specific and cytoplasmic expres-
sion of the F-actin capping protein α1 subunit
(CAPZA1) and the predominant nuclear expression of
tubulin β that was particularly visible beneath the liver
capsule may possible promote microtubule stability and
interactions of microtubules with endogenous proteins.
Furthermore, the induced and predominat cytoplasmic
expression of the GDP dissociation inhibitor 2 (GDI2)
protein is part of the control of vesicular trafficking.
This protein is known to regulate GDP-GTP exchange
amongst members of the Rab family of proteins. The
Figure 1 (See legend on next page.)
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Figure 1 Liver proteome mapping of healthy non-transgenic control and EGF transgenic mice. (A) Histopathology of a well-organized normal liver
tissue of a non-transgenic control (image magnification 25-fold). (B) Histopathology of completely disorganized tissue of advanced HCC showing
multilayered hepatocytic trabeculae besides solid areas, peliosis-like intratumourous vasectasias and focal necroses (light red) (image magnification
25-fold). (C) Zoom-in 2D gel image of healthy non-transgenic control liver extracts in the pH range of 5–8. (D) Zoom-in 2D gel image of healthy
non-transgenic control liver extracts in the pH range of 7–10.Panel E to G depict examples of zoom-in 2D gels of regulated proteins. (E) Spot
1: glycine N-methyltransferase, identified in control samples only; Spot 2: peroxiredoxin 6, up-regulated in tumour samples; Spot 3: peroxiredoxin 6,
down-regulated in tumour samples; Spot 4: lysophospholipase 1, down-regulated in tumour samples; Spot 5: hypothetical protein LOC68347,
down-regulated in tumour samples; Spot 6: glutathione peroxidase 1, down-regulated in tumour samples. (F) Examples of up-regulated mouse
liver proteins: fibrinogen β (I), vimentin (II), Cu/Zn superoxide dismutase (III), and apolipoprotein E (IV). (G) Examples of down-regulated mouse
liver proteins: arginase 1 (I), Dhdh protein (II), glutathione peroxidase 1 (III) and predicted: agmatine ureohydrolase (IV).
Borlak et al. BMC Genomics  (2015) 16:124 Page 13 of 29tumour specific and cytoplasmic expression of amphiregu-
lin supports the notion of a switch in autocrine signalling
and it has been reported that amphiregulin is a prognostic
marker for poor outcome of a variety of malignancies in-
cluding colorectal liver metastasis [64]. Finally, the re-
pressed nuclear expression of HNF4A was not unexpected
and confirms earlier findings [62].
Comparison of disease regulated proteins in mouse and
human HCC
Based on the information given in Table 1 the Human
Protein Atlas depository (www.proteinatlas.org, version
12) was interrogated. As shown in Additional file 4:
Table S4 48 out of 96 mouse liver cancer regulated pro-
teins were likewise regulated in human HCC. It should
be noted that for some proteins several antibodies were
used to study their expression; only representative data
were considered. Importantly, out of the 54 proteins
uniquely expressed in mouse liver tumours n = 11 were
likewise uniquely expressed in human HCC thus eviden-
cing clinical significance of our findings.
Comparison of gene and protein expression in EGF
induced liver cancer
We compared our previously published transcriptomic
data of EGF induced liver cancers with the proteomicTable 2 Proteins regulated in common in tumour tissue and s
No. Protein Accession numbe
1 Alpha-fetoprotein gi|42542817
2 Apolipoprotein A1 gi|26345182
3 Apolipoprotein E gi|6753102
4 Carboxylesterase precursor gi|2921308
5 Fibrinogen, alpha polypeptide gi|33563252
6 Fibrinogen, beta polypeptide gi|33859809
7 Fibrinogen, gamma polypeptide gi|19527078
8 Major urinary protein 1 gi|8569601
9 Pzp (A2mg protein) gi|34785996
10 Serum amyloid P-component gi|38174334data obtained in the present study. Such comparisons re-
vealed n = 22 genes to be significantly regulated of which
n = 17 are in common regulated whereas for n = 5 genes
transcript expression was opposite to that of the coded
proteins (see Additional file 5: Table S5).
Classifications of disease regulated protein by Gene
Ontology (GO)
82 of the 96 significantly regulated proteins were mapped
to 40 different biological processes (see Figure 4A) of
which prominent examples are regulation of arginine me-
tabolism and amino acid import, regulation of CDC42 pro-
tein signal transduction’ , cellular response to oxidative
stress, hydrogen peroxide and superoxide, glycolysis
and gluconeogenesis, regulation of cholesterol transport,
protein-lipid complex and plasma lipoprotein particle re-
modeling, positive regulation of steroid metabolic process,
negative regulation of calcium ion transmembrane trans-
porter activity and release of sequestered calcium ion into
cytosol by sarcoplasmic reticulum, (see Additional file 6:
Table S6).
In Figure 4A-C the GO biological process, cellular
components and molecular functions are depicted.
Note, some of the ontology terms could be grouped, i.e.
chaperone-mediated protein complex assembly and fold-
ing, endoplasmic reticulum unfolded protein response,erum of EGF transgenic mice
r RatioHCC/control (serum) RatioHCC/control (liver)
2 up (by Western blot)








Spot 1: 1.8 tumour
Spot 2: 3.2
10 tumour
Figure 2 Western blotting of serum proteins in control and EGF transgenic mice. For the commonly regulated proteins in serum and tumours
their regulation in liver tissue was confirmed by 2DE and MALDI-TOF/MS (see Table 1). Depicted are Western blots for serum proteins. Note, with the
exception of EGF the regulated serum proteins were already reported in our earlier publication [7]. C 1–4 = individual control animals, T 1–6 = individual
tumour bearing mice. (A) alpha-fetoprotein, (B) fibrinogen gamma, (C) serum amyloid component P, (D) epidermal growth factor, (E) and apolipoprotein
M which was identified in serum samples only.
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tive stress as well as hypoxia, blood coagulation, develop-
mental growth and regulation of programmed cell death.
Cellular components and molecular functions
As depicted in Figure 4B 76 significantly regulated
proteins were mapped to 21 cellular components (see
Additional file 7: Table S7), i.e. mitochondrial crista, matrix
and inner membrane, endoplasmic reticulum lumen, early
endosome and cytoplasmic membrane-bounded vesicle,
chylomicron, very-low and high density lipoprotein particle,
proteasome accessory complex, peroxisome, extracellular
vesicular exosome and extracellular membrane-bounded
organelle.
Furthermore, 75 significantly regulated proteins were
mapped to 21 molecular functions (see Figure 4C) and in-
cluded arginase activity, fructose-bisphosphate aldolase ac-
tivity, hydrolase and oxidoreductase activity, acting on
carbon-nitrogen (but not peptide) bonds, acting on alde-
hyde, CH-OH group or oxo group of donors, NAD or
NADP as acceptor as well as steroid dehydrogenase activity.
In addition, phosphatidylcholine-sterol O-acyltransferase
activator activity, cholesterol transporter activity, sterol
transporter, antioxidant and lipid transporter activity as well
as electron carrier and serine-type endopeptidase inhibitor
activity were prominent functions. Finally, proteins func-
tioning in metal ion and purine ribonuleoside triphosphate
binding, lipoprotein particle receptor binding, chaperoneand oxygen binding, binding of magnesium ion and NAD,
protease and single-stranded DNA binding were observed
as disease regulated (Additional file 8: Table S8).
Pathway analysis of tumour proteins
In all, 96 significantly regulated proteins were classified
by the REACTOME, KEGG and WikiPathway databases,
respectively. The different databases provided similar in-
formation with the majority of tumour proteins acting in
4 major metabolic pathways (see Figure 5 and informa-
tion derived from ClueGO and CluePedia). For example,
the proteins ALDOA, ALDOC, FBP1 and PKM function in
glycolysis and gluconeogenesis whereas AKR1C6, ALDOA,
ALDOC and FBP1 are part of the fructose and mannose
metabolic pathway. Likewise, ATP5H and NDUFV1 are part
of the oxidative phosphorylation pathway and MDH1 and
PKM contribute to pyruvate metabolism. Similarly, the
proteins AKR1C14, AKR1C18, AKR1C6, ALB, APOA1,
APOA4, APOE, FDPS, GPX1, HACL1 and PLG take
part in the metabolism of lipids, arachidonic acid and lipo-
proteins whereas the proteins AGMAT, ARG1, ARG2,
BCKDHA, CKB, CPS1, HAAO and PHGDH are specified
for arginine and proline metabolism. In the same manner
the proteins GPX1, ITPA and NME1 contribute to the
metabolism of nucleotides and related to this are the pro-
teins ITPA, PKM and PSMC5 which are part of the purine
metabolic pathway. Apart from these pathways a highly
significant regulation of the blood coagulation cascade,
Figure 3 Immunohistochemistry of proteins regulated in hepatocellular carcinoma of EGF transgenic mice. Shown are images of
(A) Arginase II, (B) Capza1, (C) GDI 2, (D) Tubulin β, (E) hnRNP L, (F) Amphiregulin, (G) HNF4α and (H) Epiregulin. Specificity was determined by
treating the specimen with washing buffer instead of primary antibody (controls); in the case of amphiregulin the specificity was confirmed with
a blocking peptide.
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Figure 4 Significantly regulated proteins categorized by GO terms. (A)
Biological process, (B) Cellular components, (C)Molecular functions. The pie-
charts depict the percentage of proteins involved in the various GO terms.
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by the proteins CRK, FGA, FGB, FGG, PLG and SOD1 all
of which were highly significantly regulated. Furthermore,
tRNA aminoacylation (AARS, GARS and SARS), advanced
glycosylation endproduct receptor signalling (ALB, CAPZA1
and LGALS3), peroxisome (ECH1, HACL1 and SOD1),
protein processing in endoplasmic reticulum (GANAB,
HYOU1 and PDIA4), proteasome (PSMC5 and PSMD11)
and activation of chaperone genes by XBP1(S) and ‘unfolded
protein response’ (HYOU1 and LMNA) are pathways
significantly perturbed in liver cancer induced by EGF
(see Additional file 9: Table S9 and Additional file 10:
Table S10).
Identification of master regulatory proteins
Using the designated workflow of the GeneXplain platform
(see Methods section) we searched for master regulatory
proteins. The software is designed to identify molecules
upstream of regulated tumour proteins to assist in the con-
struction of molecular circuitries. After annotation of the
input datasets the tool “Find master regulators in networks
(GeneWays)” was used to identify key nodes amongst 54
proteins exclusively expressed in tumours (To). This re-
vealed 24 upstream regulatory molecules. Among them five
were selected for their link to the EGFR signalling pathway,
i.e. PLAUR, FGFR1, PTBP1 and AGTRAP while the protein
S100A1 was chosen for its importance in the PLAUR/EGFR
network, (see Additional file 11: Figure S1A-E).
In Additional file 3: Table S3 and Additional file 12: Table
S11, the tumour regulated proteins distributed amongst the
selected master regulatory molecules are summarized.
In support of its biological significance the constructed
networks were enriched with gene expression data from
transgenic non-tumour and tumour tissues. Thus, the
gene and protein data were merged and hybrid networks
for each master regulatory protein were constructed.
Subsequently, these were merged into one (see Figure 6)
and the integrated hybrid network consisted of n = 82
network proteins of which n = 20 were tumour specific.
In support, the genes coding for lmna, i.e. a component
of the nuclear lamina that is frequently up-regulated in
cancers and mvp that codes for multidrug resistance
were up-regulated (ur-T) whereas nme, a suppressor of
metastasis was repressed in expression (dr-T). Likewise,
the genes coding for igals3, i.e. a beta-galactoside-binding
protein frequently overexpressed in cancers and pcbp1 that
is involved in transcription and functions as an inhibitor of
invasion [65] were up-regulated in transgenic non-
tumour livers (ur-Tr-nT) whereas transcript expression
of aars, a member of tRNA synthases and anaxa6, a
calcium-dependent, phospholipid-binding protein with
important roles in the tumour microenvironment and
metastasis were repressed (dr-Tr-nT). Finally, the entire
network was enriched with expression data of 16 and
Figure 5 Molecular interaction and biological pathways networks of regulated proteins in liver tumours of EGF transgenic mice.
Cytoscape 3.0.2 with plugins (see Methods section) are used to generate functionally grouped network of pathways. Grouping of significant
pathway terms (p ≤ 0.05) were based on kappa score threshold of 0.4, initial group size of 2 and sharing group percentage of 50. The pathway
network consisted of 47 significantly regulated proteins involved in distinct pathways which are colour-coded. Note, the three individual terms
are grey-coloured. Up and down-regulated proteins are coded as orange and green small discs, respectively.
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in tumour and non-tumour transgenic livers.
Next, we searched for master regulatory molecules by
considering 82 regulated tumour proteins obtained from the
comparison tumour specific or up- and down regulated as
compared to healthy non-transgenic controls (To +UR+
DR). This revealed 29 filtered (threshold radius of 10) up-
stream regulators. Among these 7 were selected as candi-
dates because of their regulation in liver tumours and their
link to EGFR signalling. Notably, in the constructed network
all master regulators were significantly up-regulated and in-
cluded PDIA4, APEH, PEBP1 and APOE while the protein
expression of ARG1, FBP1 and HAAO was repressed
(see Additional file 13: Figure S2A-G). Note, in the case
of ARG1 transcript expression was equally repressed.
In Additional file 3: Table S3 and Additional file 12:
Table S11 the tumour regulated proteins distributed
amongst the selected master regulatory molecules are
summarized.
In support of its biological significance the fused hybrid
network was enriched for gene expression data derivedfrom transgenic non-tumour and tumour tissues. Thus,
the integrated hybrid network consisted of 34 out of 82
regulated proteins and gene expression calls evidenced 6
of the 27 up-regulated tumour (To + UR) proteins to be
regulated at the transcript level as well whereas among
the 7 down-regulated tumour proteins (DR) the gene arg1
was repressed in expression. Likewise, gene expression
data from non-tumour transgenic livers evidenced 5 genes
out of 27 networks partners to be increased in expression
(ur-Tr-nT) and among the 7 down-regulated networks
proteins the gene phb was repressed (dr-Tr-nT). Thus,
when the tumour gene expression data of the entire net-
work was considered a total of 22 genes were regulated, of
which 13 were up-regulated and 9 were repressed in ex-
pression, (see Figure 7).
Protein interaction network
Based on the information of the hybrid master regulatory
network and in addition to other disease regulated pro-
teins summarized in Table 1 (note, some of the proteins
were not part of the networks) a total of n = 122 disease
Figure 6 Integrated master regulatory network for proteins uniquely expressed in tumours. Based on network information obtained for the
5 different master regulators an integrated hybrid network was constructed. The network contained 82 proteins including 20 with connectivity to EGFR
signalling (yellow coloured inner node). The master regulator, the connecting proteins (network elements) and regulated proteins are given as red,
green and blue coloured inner node, respectively. Furthermore, each node is partitioned into four segments whereas the first segment seen from left
refers to tumour specific proteins and is red-coloured. The second, third and fourth segments refer to either up- and down-regulated proteins, tumour
specific gene expression changes and gene regulations in transgenic non-tumour liver tissue, respectively. Increased expression of either proteins or
genes is given in red, whereas the blue colour denotes repressed expression.
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tion. After filtering for non-connected proteins the STRING
database informed on n = 151 protein-interactions of which
n = 76 were disease regulated as identified in the present
study. Among these 45, 24 and 7 were either up-, down- or
not statistically significantly regulated. Furthermore, gene
expression calls for 45 up-regulated proteins were supported
by 5 up- and 4 down-regulated genes identified in tumours
and 4 up- and 6 down-regulated genes in transgenic
non-tumour livers. Likewise, gene expression calls for 24
down-regulated proteins were supported by 8 and 5 down-
regulated genes in tumours and transgenic non-tumour
livers, respectively. Therefore, the entire network was sup-
ported by 14 induced and 17 repressed tumour specific gene
expression changes and 16 up-regulated and 13 down-
regulated genes observed in transgenic non-tumour livers.
As depicted in Figure 8 the proteins of the fusion network
displayed functional associations via the EGF/EGFR network
and included 69 out of 96 (72%) significantly regulated
tumour proteins with 6 out of 7 master regulators being
connected to EGFR through the network’s proteins (see
Additional file 14: Table S12 for possible protein-protein in-
teractions and related scores).Pathways mapping of fussed network proteins
Of the 151 network proteins 109 could be mapped to
distinct pathways. After removal of non-relevant terms
such as Alzheimer disease a total of 94 proteins were
mapped to 6 pathways with meaningful associations
(see Figure 9) and consisted of ‘platelet activation,
signalling and aggregation (platelet degranulation)’ ,
‘lipoprotein metabolism’, ‘MAPK signalling pathway’,
‘glycolysis and gluconeogenesis’ , ‘metabolism of amino acids
and derivatives (arginine and proline metabolism)’ , ‘apop-
tosis’ and ‘EGFR1 signalling pathway’. Additionally, a total of
2 and 3 tumour regulated proteins were mapped to the
HIF-1 signalling and protein processing in endoplasmic
reticulum pathways, respectively. The pathway mapping was
also supported by gene expression data with 10 up- and
9 down-regulated genes in tumours and 9 up- and 6 down-
regulated genes in transgenic non-tumour livers. Note, two
of the significantly regulated tumour proteins, i.e. CRK and
PEBP1 are members of the EGFR1 signalling pathway with
PEBP1 also functioning as a master regulator while the
other regulated proteins are connected to EGFR signalling
through cross-talk among the pathways (see Additional file
15: Table S13).
Figure 7 Integrated master regulatory network for HCC regulated proteins. Based on network information obtained for 7 different master
regulators an integrated hybrid network was constructed. The network contained 114 proteins including 34 with connectivity to EGF/EGFR
signalling (yellow coloured inner node). The master regulator, the connecting proteins (network elements) and regulated proteins are given as
red, green and blue coloured inner node, respectively. Furthermore, each node is partitioned into four segments whereas the first segment seen
from left refers to tumour specific proteins and is red-coloured. The second, third and fourth segments refer to either up- and down-regulated
proteins, tumour specific gene expression changes and gene regulations in transgenic non-tumour liver tissue, respectively. Increased expression
of either proteins or genes is given in red, whereas the blue colour denotes repressed expression.
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Recent research into the molecular pathogenesis of HCC
evidenced significant alterations in signalling pathways.
Given the fact that the epidermal growth factor is an im-
portant mitogen for hepatocytes we were particularly in-
terested in investigating the consequences of its targeted
overexpression in the liver. In our previous study we
employed chromatin immunoprecipitation followed by
cloning and sequencing of DNA to search for tumour
associated gene regulations targeted by novel HNF4al-
pha P1 and P2 promoter-driven isoforms. This identified
EGF-receptor substrate (EPS15R) and EPS15 as regu-
lated by the P2 promoter-driven HNF4alpha splice vari-
ant in mouse and human HCC. A molecular circuitry
was proposed whereby EPS15 and EPS15R mediate in-
ternalization of activated EGFR to stimulate receptor re-
cycling, therefore responding to mitogenic signalling of
EGF [66]. In the present study disease proteomics wasperformed to further investigate the role of EGF in liver
cancer. This identified 122 regulated proteins of which
37 are novel and have not been reported so far.
Extra-cellular space and secreted proteins
A total of 63 proteins were significantly up-regulated
(Table 1). Among these 18 were extra-cellular or se-
creted proteins and included albumin and isoforms of it,
apolipoproteins (ApoE, ApoA4 and ApoAI), α-, β-, γ-
fibrinogen, plasminogen as well as interleukin 1 receptor
antagonist (IL-1RA). Note, an isoform of ApoA1 was
already proposed as serum marker of HCC [67] and
based on IHC staining IL-1RA expression was confirmed
in about 70% of mouse liver adenoma and carcinoma cases;
however preneoplastic foci as well as normal hepatocytes
surrounding the lesions were negative. Furthermore, RT-
PCR analysis confirmed mouse hepatic tumours to contain
both secreted and intracellular forms of IL-1ra [51] and
Figure 8 STRING protein-protein interaction network. The network consisted of 69 statistically significantly up- and down-regulated proteins
and 7 regulated proteins which failed to reach statistical significance. This STRING protein-protein network is a confidence view and a required
default confidence score of 0.4 was set. The protein network depicts interaction of regulated proteins including master regulators connected to
EGFR signalling.
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efficacy of radiofrequency ablation in HCC patients [68].
Mitochondrial proteins
An important finding of the present study is the statisti-
cally significant regulation of 20 mitochondria associated
proteins of which 13 were repressed while 7 were up-
regulated. Similar results were reported by Chignard and
Wei Sun with mitochondrial proteins being the second
largest proportion of regulated proteins in human viral
HCC [15,69]. Among the repressed proteins were
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex
8 and prohibitin, a mitochondrial chaperone. This protein,
when deleted (prohibitin KO mice) induced fibrosis, bile
duct metaplasia, liver dysplasia and eventually multifocal
HCC. However, its overexpression in tumour cell lines
inhibited cell proliferation to demonstrate tumour sup-
pressor function [70]. Likewise, glutathione peroxidase 1
(response to oxidative stress) and argininosuccinate syn-
thetase 1 (ASS, urea cycle) were repressed. Note, ASS isthe first of two enzymes to convert citrulline to arginine
and this pathway allows cells to synthesize arginine from
citrulline to function in NO production, ammonia detoxi-
fication and synthesis of polyamines. Several reports sug-
gest ASS deficiency to be common in tumour cell lines
[25-30], and the present study confirms ASS expression to
be confined to healthy non-transgenic control liver, but
ASS was absent in tumour tissue extracts (see Table 1).
Ablation of ASS in diverse tumours suggests a tumour
suppressor function and the fact that forced expression of
ASS in osteosarcoma cell lines suppresses growth adds
weight to this notion [71].
Another example of tumour specific ablation of pro-
teins refers to glycine N-methyltransferase (GNMT).
The enzyme catalyzes the transfer of a methyl group
from S-adenosylmethionine (SAM) to glycine thereby gener-
ating S-adenosylhomocysteine and N-methylglycine. This
protein was completely downregulated in liver tumours.
GNMT is known to play a role in the maintenance of gen-
etic stability [44,72], and a novel tumour suppressor function
Figure 9 Pathways mapping of fussed network proteins. Cytoscape 3.0.2 with plugins (see Methods section) are used to generate functionally
grouped network of pathways. Grouping of significant pathway terms (p ≤ 0.05) were based on kappa score threshold of 0.4, initial group size of 2 and
sharing group percentage of 50. The pathway network consisted of 35 significantly and 7 non-significantly regulated proteins involved in distinct
pathways which are colour-coded. Note, the two individual terms are grey-coloured. Up and down-regulated proteins are coded as orange and green
small discs, respectively. Up- and down-regulated as well as non-significantly regulated proteins and connecting proteins of the network are given as
orange, green, yellow and blue coloured discs, respectively. The network depicts protein-protein interactions in liver tumours of EGFR transgenic mice
and their relation to various pathways under the influence of EGFR signalling. EGFR is highlighted as blue triangle in this network.
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activity but does require its nuclear localization [73].
Newly identified disease-regulated proteins
Several of the proteins listed in Table 1 were already re-
ported for their tumour specific regulation while proteins so
far unknown for their regulations in HCC, are marked with
an asterisk (Table 1). These function in diverse biological
processes including metabolism, translation and signalling.
Specifically, changes in carbohydrate metabolism are com-
monly observed in tumours where energy production relies
on glycolysis rather than mitochondrial oxidative phosphor-
ylation. In the present study induced expression of several
glycolytic enzymes was observed, most notable [1] pyruvate
kinase 3 that catalyzes the transfer of a phosphate group
from phosphoenolpyruvate to ADP and was shown to be a
target of mi-RNA122 in HCC [2,74] aldolase, an enzyme
that converts fructose 1,6-bisphosphate into dihydroxyacet-
one phosphate (DHAP) and glyceraldehyde 3-phosphate
and was reported to be a sensitive marker for benign and
malignant liver disease [75] and [3] alpha glucosidase 2, a
hydrolase that cleaves glycosidic bonds with the release of
alpha glucose from carbohydrates.Further important findings include the tumour specific
expression of alanyl-, glycyl- and seryl-tRNA synthetases
which catalyze the transfer of specific amino acids to
tRNA, as well as regulation of eukaryotic translation
elongation factor 2 and Poly(rC) protein 2 that binds to
oligo dC. Note, knowledge on the role of aminoacyl-tRNA
synthetases in cancer is just emerging [76] and through the
use of a lentiviral mediated shRNA vector, a link between
aminoacyl-tRNA synthetases [AARS]-interacting multi-
functional protein 2 (AIMP2) and repressed EGFR signal-
ling was established that resulted in repressed glucose
uptake [77]. We also observed induced expression of het-
erogeneous ribonucleoprotein (hnRNP) that takes on di-
verse functions in the processing of mRNA. Its expression
was reported to be increased in serum of HCC patients. In
contrast, proteins involved in the synthesis and degradation
of cholesterol, lipids, steroids and fatty acid were in part op-
positely regulated and included induced expression of the
aldo-keto reductase family 1. Regulation of this protein has
been reported for lung and pancreatic cancers [78], and
gene silencing of aldo-keto reductase family 1 B10 resulted
in growth inhibition of colorectal cancer cells that might be
of therapeutic utility [79]. The repressed expression of
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sponse and includes the enzyme enoyl coenzyme A hydra-
tase 1. Its activity was shown to contribute to lymphatic
spread of liver tumours as was evidenced in gene silencing
studies [80]. Likewise, we observed repressed expression of
dihydrodiol dehydrogenase in tumours. This enzyme plays
an important role in the metabolism of steroids that leads to
inactivation of circulating androgens, progestins and gluco-
corticoids and was repeatedly reported to be overexpressed
in non-small cell lung cancer. Amongst patients with high
DHD expression the incidence of early tumour recurrence
and distant metastasis is significantly higher and patients are
highly resistant to chemo and radiotherapy [81].
Intriguingly, complete ablation of mitochondrial butyryl
coenzyme A synthetase 1, a GTP-dependent lipoate-
activating enzyme was observed in tumours of EGF
transgenic mice. Little is known about the possible link
between butyrate metabolism and liver cancer. However,
butyrate is well known to inhibit proliferation of human
colon carcinoma cells in an epigenetic manner that in-
volves histone acetylation [82]. Note, it was recently re-
ported that due to the Warburg effect butyrate-mediated
histone acetylation and cell proliferation is dictated [83].
Several lines of evidence therefore suggest butyrate to act
as a cytosolic sensor for histone acteylation and when
transformed to intermediates by butyryl coenzyme A syn-
thetase is unable to escape the mitochondria.
Moreover, we observed a highly significant repression of
2-hydroxyphytanoyl-CoA-lyase. This peroxisomal thiamine
pyrophosphate-dependent enzyme is rate limiting in the
breakdown of 2-hydroxy fatty acids. The biological role of
2-hydroxy fatty acids has only recently become apparent
[84] and cumulative evidence suggests intermediates of en-
ergy metabolism to specifically activate G-protein coupled
receptors which are now classified as hydroxy carboxylic
acid receptors (HCA1-3). The HCA2 receptor is involved
in a complex negative feed-back loop whereby ketone bod-
ies derived from fatty acid oxidation are sensed by HCA2
via the activity of 3-hydroxybutyrate that leads to inhibition
of lipolysis and to restriction of further fatty acid supply. In
this way triglyceride use is diverted and energy demands for
tumour growth are met more efficiently. Specifically, during
rapid tumour growth and the herewith associated ischemia
the yield of high energy bonds (ATP) from glucose oxida-
tion is about twice that of fatty acid oxidation. Our observa-
tion that proteins involved in the ß-oxidation of fatty acids
were either repressed or unchanged agrees well with this
principle (see also discussion below).
The reduced expression of lysophosphopholipase signi-
fies an adaptive response; it catalyses the production of
lysophosphatidic acid, i.e. a second messenger known to
contribute to tumour cell motility, survival and prolifera-
tion [85]. Additionally, the repressed expression of mito-
chondrial acyl-CoA thioesterase 1 in liver tumours whichhydrolyzes acyl-CoAs to free fatty acids and coenzyme A,
will influence the supply of ligands for nuclear receptors
and the regulation of fatty acid oxidation in mitochondria
and peroxisomes. Equally, the regulation of farnesyl di-
phosphate synthetase, i.e. a key enzyme in the isoprenoid
biosynthetic pathway is highly interesting and this enzyme
is explored as a drug target of bisphosphonates to treat
tumour growth [86]. It’s up-regulation in colon cancers
was reported [39]. In the present study repressed expres-
sion of the ribosom-compononent RPS12 and enzymes of
amino acid metabolism like branched chain ketoacid de-
hydrogenase E1 as well as dimethyl glycine dehydrogease
was observed. Conversely, expression of the proteasome 26S
ATPase subunit 5 (p45/SUG) and its non-ATPase regulatory
subunit 11 (PSMD11) was confined to tumour tissues (see
Table 1); the latter subunit is known to display high activity
in embryonic stem cells. This multicomplex molecular ma-
chinery degrades intracellular proteins marked up by ubiqui-
tin chains. PSMD11 was reported to be up-regulated in
breast cancer cells [87].
Enhanced expression of cytoskeletal proteins such as
tubulin β 5 and CAPZA1 was also confirmed by IHC
staining (see Figure 3). Differences in the localization of
these proteins were obvious with tubulin ß 5 expression
being primarily associated with cells proximal to the
liver capsule, whereas expression of capping protein Z-
line α1 (CAPZA1) was strongly associated with tumour
foci and this protein is known to play a pivotal role in
cytoskeletal networks to support cell mobility, invasion
and metastasis. Additionally, GDI2, a protein function-
ing in the cycling of Rab GTPases and arginase II, i.e. a
non-liver isoform of the urea cycle were up-regulated in
tumours of EGF transgenic mice (see Figure 3). Regula-
tion of arginase II was observed in various malignancies
including lung cancer [88]. Besides, the actin-binding
protein LASP1 was uniquely expressed in tumours and
is also up-regulated in breast cancer [89] to possibly sup-
port migration of cancer cells [90]. Furthermore, PDIA4, a
disulfide bond isomerase and master regulator of the con-
structed networks (see below) was up-regulated as was
kininogen that is part of the blood coagulation system and
functions as a precursor of kinin. Conversely, the serinpro-
teinase inhibitor Serpinb1a was repressed in expression to
possible limited immunological responses in tumour growth
and to influence inflammatory cytokine production by infil-
trating monocytes [91].
The significant regulation of the calcium binding protein
sorcin and nucleobindin 1 are further highly interesting re-
sults. Sorcin is associated with multidrug-resistance in hu-
man leukemia cells [92] and nucleobindin 1 is evaluated as
a biomarker of colon cancer [93]. In EGF induced liver tu-
mours transthyretin was also up-regulated. This protein is
involved in the transport of thyroid hormones and was re-
ported to be aberrantly regulated in thyroid cancer [94].
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CT10. This oncoprotein interacts with several tyrosine-
phosphorylated proteins and is part of the intracellular
signalling cascades notably the phosphoinositide 3-kinase
(PI3K)/AKT pathway [95]. Likewise, regulation of the
170 kDa glucose-regulated protein GRP170 is of great im-
portance. This lumenal endoplasmic reticulum plays a
role in immunoglobulin folding as was confirmed by co-
immunoprecipitation in four different B cell hybridoma cell
lines [11]. In our previous study several immunoglobulins
were found to be either repressed or absent in serum of
EGF tumour bearing mice and this was particularly obvious
for the Ig K and L classes [7]. It remains to be determined
whether repression of immunoglobulins can be attributed to
aberrant GRP170 activity.
A summary of the biological functions in addition to their
previous reported tumour association is given in Additional
file 16: Table S14 while the regulation of genes coding for
newly identified proteins and of genes coding for com-
monly regulated proteins in liver tumours and serum of
EGF2B-transgenic mice is given in Additional file 17: Table
S15 and Additional file 18: Table S16.
Master regulatory networks
Initially the network construction was based on proteins
exclusively expressed in tumours and by selecting master
regulatory proteins linked to EGFR signalling. Thereafter, a
fused hybrid network was developed in which tumour spe-
cific proteins were part of it. Subsequently, the search was
extended to all significantly regulated proteins (Table 1).
This revealed 7 master regulatory proteins and its associ-
ated networks and encompassed 114 proteins of which 34
were disease regulated. Eventually a fused network was de-
veloped; however not all disease regulated proteins are part
of it. The performed pathway mapping over fused networks
(see STRING analysis) defined protein interactions and
grouped 76 disease regulated proteins into 6 distinct path-
ways of which platelet activation, signalling and aggregation
is a major one (see Figure 8).
Specifically, the glycoprotein fibrinogen is a multimeric
protein and consists of α, ß and y subunits. It is synthe-
sized by hepatocytes and an essential blood coagulation
factor with all polypeptide chains being highly regulated
in tumours of EGF transgenic mice. Note, an association
between coagulation factors and malignancies was estab-
lished whereby fibrinogen functions as an extracellular
matrix protein to interact with integrin receptors in the
control of cell proliferation and cell migration [96]. Ac-
cordingly, induced gene expression of the integrin recep-
tors Itgb1, Itga3 and Itgav was observed in EGF induced
liver tumours. In cancer progression a regulatory loop
between fibrinogen, platelets and tumour cells has been
determined that is activated by platelet cytosolic Ca2+.
This second messenger induces integrin receptor complexformation through an association of platelet glycoprotein
chains IIb and IIIa (CD41/CD61) thereby creating an ac-
tive binding site for fibrinogen. An association of tumour
regulated proteins with the regulatory loop was confirmed
in STRING analysis (Figure 8) and fibrinogen was re-
ported to be an important determinant for metastasis of
circulating tumour cells [97]. It is therefore of no surprise
that elevated blood fibrinogen is a poor prognostic factor.
Haemostatic complications are commonly observed in
cancer patients and future therapeutic strategies may focus
on the hemostatic system by targeting tumour stroma. In
this regard the tumour specific induction of plasminogen is
of great importance. This zymogen [98] is converted to
plasmin by urokinase (UPA), a serine protease which itself
was unchanged; however, gene expression of its receptor
was significantly up-regulated in transgenic non-tumour
livers. One report suggests the urokinase receptor to prime
cells for proliferation in response to EGF by promoting
Tyr845 phosphorylation and Stat5b activation; nonetheless,
this depended on intracellular c-Src levels [99].
Further studies established a link between induced ex-
pression of plasminogen activator, uPA receptor and
plasminogen activator inhibitor type-1 (PAI-1) and inva-
siveness and metastasis of HCC [100,101]. Indeed, a fine
balance exists between the plasminogen activating sys-
tem and its inhibition by PAI-1 and PAI-2. Based on
transcriptomic data a highly significant induction of
PAI-I (up to 12-fold) in large tumours of EGF transgenic
mice was observed [6]; consequently, the regulation of
components of the plasminogen activating system may
be considered as part of a strategy to degrade extracellu-
lar matrix thereby facilitating invasion and metastasis
[102,103].
To meet energy demands efficiently different sources
are utilized and the induction of the proteins ALDOA,
ALDOC, ENO1, PKM and FBP1 is testimony to an altered
glycolytic and pentose phosphate pathway. However, with
the exception of acyl-CoA thioesterase 2 that was below
the limit of detection and functions in the hydrolysis of
myristoyl- palmitoyl-, stearoyl- and arachidoyl-CoA esters
the regulation of enzymes linked to fatty acid metabolism
in mitochondria and peroxisomes was hardly observed.
In pursue of tumour growth and to sustain organelle
and membrane biogenesis lipids are de novo synthesized
and mobilized from stores and while the complex inter-
action of hepatic lipid and glucose metabolism in liver
disease is the subject of intense research [104] the
present study evidences significant regulation of several
apolipoproteins, i.e. APOE, APOA1, APOA4 and iso-
forms of albumin. Apart from lipid transport apolipo-
proteins play a wider role in cancers and are known to
interact with diverse receptors to elicit cellular events as
demonstrated for APOE to cause sustained proliferation
and survival of cancer cells [105].
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keto reductases. Their quantitative evaluation in different
hepatocellular carcinoma (HCC) cell lines was recently re-
ported [106]. This superfamily of proteins comprises NAD
(P)(H)-dependent enzymes which catalyze oxidoreduction
of a variety of prostaglandins, steroids and toxic aldehydes.
Their involvement in tumorigenesis is supported by several
studies and they are explored as drug targets to overcome
chemoresistance. In the present study the aldo-keto reduc-
tases AKR1C14, AKR1C18 and AKR1C6 were uniquely
expressed in tumours, however glutathione peroxidase 1
was repressed to 30% of healthy control livers to possibly
support HIF-1 signalling. Indeed, the redox state and
therefore glutathione participates in the hypoxic induction
of HIF-1 [107], and two proteins of the glycolytic pathway,
i.e. ALDOA1 and ENO1, which respond to HIF-1 signal-
ling, were regulated. Moreover, glutathione peroxidase 1
was shifted in the gel as shown in Figure 1 panel G III as a
result of post translational modifications that most likely
involved c-Abl and Arg kinase activity at Tyr 96 of GPX1
[108]. Likewise, the genes coding for Aldo1 and Eno3 were
significantly up-regulated in EGF induced liver tumours.
A complex interaction exists between EGFR and
RAGE signalling. This receptor for advanced glycation
end-products is a member of the immunoglobulin family
of cell surface molecules and was reported to significantly
influence hepatic tumour growth in murine models of
colorectal carcinoma [109]. There is strong evidence for
RAGE to promote cancer growth upon ligand dependent
activation and several proteins of the S100 family bind to
the extracellular domain of RAGE [110,111]. It is of con-
siderable importance that gene expression of S100a4 and
S100a11 was up to 34-fold induced in tumours of EGF
transgenic mice, however expression of S100a1 was re-
pressed. Likewise the tumour specific expression of the
RAGE binding proteins lectin, galactoside-binding, sol-
uble, 3 and CAPZA1 in tumours of EGF transgenic mice
is highly suggestive for a sustained crosstalk between
RAGE and EGFR [112]. Although the precise mechanism
by which S100 proteins stimulate EGFR signalling remains
to be elucidated binding of S100A4 to EGF and to other
EGFR ligands was reported to possibly facilitate inter-
action with the receptor [113]. Similarly, the binding of
S100A8/A9 to RAGE was shown to promote migration
and invasion of human breast cancer cells through actin
polymerization and epithelial–mesenchymal transition
[114]. Conversely, advanced glycation endproduct (AGE)
receptor 1 suppressed oxidant stress-dependent signalling
via the EGFR and Shc/Grb2/Ras pathway [115].
As depicted in Figure 5 the amino acid metabolism was
another distinct pathway to which several of the regulated
proteins could be mapped to. Note, the tumour specific
regulations of arginine 1 and 2 as well as the regulation of
subunits of the proteasome 26S ATPase (PSMC5 andPSMD11) were already discussed (see above). In the fol-
lowing additional proteins regulated in this pathway are
briefly summarized.
Specifically, 3-hydroxyanthranilate-3,4-dioxygenase (Haao)
catalyzes oxidation of 3-hydroxyanthranilate to quinolinate
and this intermediate functions as a precursor in NAD and
pyridine biosynthetic pathways. Expression of Haao was sig-
nificantly repressed in tumours of EGF transgenic mice and
hypermethylation of the coding gene was observed in ovar-
ian cancer [116]. Due to the fact that Haao is significantly
repressed at the gene and protein level in at least two differ-
ent tumour entities (ovarian and liver cancer) the protein
may function as a tumour suppressor that appears to be re-
pressed by an epigenetic mechanism.
A significant finding is the tumour specific expression
of 3- phosphoglycerate- dehydrogenase which catalyses
the production of 3-phosphoglycerate. This intermediate
of glycolysis is an essential precursor of the serine
biosynthetic pathway. Importantly, a recent metabolomic
study evidenced 3-phosphoglycerate to be diverted into
serine and glycine metabolism and repressed expression
of 3-phosphoglyceratedehydrogenase resulted in im-
paired tumour cell proliferation [117]. In support of
tumour growth the diversion of intermediate of
glycolysis affects protein, membrane lipid and nucleo-
tide synthesis.
Moreover, the observed induction of creatine kinase in
tumours of EGF transgenic mice creates a circuitry for
cellular energy homeostasis in conditions of high meta-
bolic demands [118]. The enzyme catalyses the revers-
ible transfer of phosphate from phosphocreatine to ADP
to yield ATP and creatine. Its induction has been ob-
served in many cancers including liver cancer cell lines
[119,120] and a further study suggested a possible inter-
play between p53 mutations, HCC, CK expression with
growth-inhibitory effects of cyclocreatine in HCC [121].
While the rationale of tumour cells in embarking on
abnormal metabolism had already been discussed (see
above) the finding that agmatine ureohydrolase was
strongly repressed in EGF induced liver tumours to
about 10% of non-transgenic healthy livers is of great
importance. This enzyme hydrolyzes agmatine (= decar-
boxylated arginine) to form putrescine and urea and re-
pression of the enzyme will significantly increase
agmatine tissue concentration to influence diverse cel-
lular control mechanisms. Importantly, in the study of
Battaglia and coworkers [122] 1 mM agmatine induced
large amounts of superoxide production in rat liver
mitochondria; however, it did not affect mitochondrial
respiration or redox levels of thiols and glutathione.
Furthermore, ATP synthesis remained normal and pre-
vented Ca(2+)-induced mitochondrial permeability
transition in the presence of phosphate to suggest an
intriguing regulatory loop whereby H2O2 induces hypoxia
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by selecting interconnected physiological pathways tumour
cells are equipped to avoid programmed cell death
[122,123]. Thus, arginine deprivation is evaluated for its
utility in cancer therapy [124].
A further enzyme repressed to 20% of healthy non-
transgenic liver is carbamoyl phosphate synthetase 1
(CPS1), i.e. a liver specific ligase to function in ammo-
nia detoxification. It is perplexing that tumour cells dis-
able such an important pathway of the urea cycle.
However, a recent study demonstrated DNA hyperme-
thylation as a key mechanism of silencing CPS1 gene
expression in human HCC. Note, forced expression of
CPS1 induced cell proliferation and the observed
repression in human HCC may simply be the result of
genomic instability as was observed in tumour cells
[125].
Conclusion
The present study identified novel disease regulated pro-
teins induced by overexpression of EGF to provide new
insight into the complex signalling events in HCC. Six
major pathways perturbed by EGFR hyperactivity were
identified and several of the regulated proteins are inter-
esting drug target candidates and this includes tumour
specific expression of kinases as well as proteins in-
volved in aberrant metabolism. An identification of com-
monly regulated proteins in tumour and sera will be of
great utility in the development of biomarkers to moni-
tor disease progression and responses to therapy.
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regulated, (C) the PTBP1 network consists of 44 proteins of which 18 are
tumour-specifically regulated, (D) the AGTRAP network consists of 43 proteins
of which 19 are tumour-specifically regulated and (E) the S100A1 network
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networks display connectivity to EGFR signalling (yellow coloured inner node)
and in the case of the S100A1 master regulatory protein EGFR s
ignalling is via the PLAUR/EGFR network.The master regulator, the connecting
proteins (network elements) and regulated proteins are given as red, green
and blue coloured inner node, respectively. Furthermore, each node is
partioned into four segments whereas the first segment seen from left
refers to tumour specific proteins and is red-coloured. The second, third
and fourth segments refer to either up- and down-regulated proteins,
tumour specific gene expression changes and gene regulations in transgenic
non-tumour liver tissue, respectively. Increased expression of either proteins or
genes is given in red, whereas the blue colour denotes repressed expression.
Additional file 12: Table S11. Integrated hybrid network with master
regulator information for proteins expressed in tumours only (To) and
significantly regulated proteins when compared to heathy liver of
non-transgenic control animals (T + UR + DR).
Additional file 13: Figure S2. Master regulatory networks for regulated
proteins with link to EGFR signalling: (A) The PDIA4 network consists of
68 proteins including 32 significantly regulated proteins, (B) the APEH
network consists of 68 proteins including 32 significantly regulated
proteins, (C) the PEBP1 network consists of 63 proteins including 31
significantly regulated proteins, (D) the APOE network consists of 66
proteins including 31 significantly regulated proteins, (E) the ARG1
network consists of 67 proteins including 31 significantly regulated
proteins, (F) the FBP1 network consists of 69 proteins including 31
significantly regulated proteins, (G) the HAAO network consists of 66
proteins including 32 significantly regulated proteins. Note, all networks
display connectivity to EGF protein (yellow coloured inner node). The
master regulator, the connecting proteins (network elements) and
regulated proteins are given as red, green and blue coloured inner node,
respectively. Furthermore, each node is partioned into four segments
whereas the first segment seen from left refers to tumour specific
proteins and is red-coloured. The second, third and fourth segments refer
to either up- and down-regulated proteins, tumour specific gene
expression changes and gene regulations in transgenic non-tumour liver
tissue, respectively. Increased expression of either proteins or genes is
given in red, whereas the blue colour denotes repressed expression.
Additional file 14: Table S12. Protein interaction information of the
fused network. Given are interacting proteins with association score from
different prediction methods, i.e. Neighborhood, Gene Fusion, Co-occurrence,
Co-expression, Databases and Textmining.
Additional file 15: Table S13. Biological pathways and their cluster for
fused network proteins. REACTOME, KEGG and WikiPathways database
information was used as input data file for Cytoscape 3.0.2. The table
shows grouping of significant pathway terms (p ≤ 0.01) and is based on
a kappa score of 0.4, initial group size of 2 and sharing group
percentage of 50.
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